- Email: [email protected]
Reply to: ‘Ziprasidone-induced acute laryngeal dystonia’
Progress in Neuro-Psychopharmacology & Biological Psychiatry 31 (2007) 971 www.elsevier.com/locate/pnpbp
Reply to the Letter to the Editor Reply to: ‘Ziprasidone-induced acute laryngeal dystonia’
References
Dear Sir,
Duggal HS. Ziprasidone-induced Acute Laryngeal Dystonia. Prog Neuropsychopharmacol Biol Psychiatry 2007;31:970. Miyamoto S, Duncan GE, Marx CE, Lieberman JA. Treatments for schizophrenia: a critical review of pharmacology and mechanisms of action of antipsychotic drugs. Mol Psychiatry 2005;10:79-104. Rosenfield PJ, Girgis RR, Gil R. High-dose ziprasidone-induced acute dystonia. Prog Neuropsychopharmacol Biol Psychiatry 2007;31:546–7.
We appreciate Dr. Duggal's interest in our case report (Rosenfield et al., 2007). We feel that his report of an acute laryngeal dystonia after treatment with ziprasidone (Duggal, 2007), in addition to our case report of a more generalized ziprasidone-induced dystonic reaction (Rosenfield et al., 2007) will help to increase awareness of the risks of these reactions with second generation antipsychotics. Dr. Duggal's patient was next treated with a relatively high dose of risperidone (i.e., 8 mg) and did not experience any further laryngeal dystonias (Duggal, 2007). This may have been because he was treated with prophylactic benztropine given the potentially increased risk of extrapyramidal side effects at higher doses of risperidone (Miyamoto et al., 2005). Further research needs to be done to understand which individuals are at greatest risk for dystonic reactions after treatment with the newer second generation antipsychotics, such as ziprasidone.
0278-5846/$ - see front matter © 2007 Elsevier Inc. All rights reserved. doi:10.1016/j.pnpbp.2007.01.026
Ragy R. Girgis* Paul J. Rosenfield Roberto Gil Department of Psychiatry, Columbia University, New York State Psychiatric Institute, United States ⁎ Corresponding author. E-mail address: [email protected]. 27 January 2007
Reply to the Letter to the Editor Reply to: ‘Ziprasidone-induced acute laryngeal dystonia’
References
Dear Sir,
Duggal HS. Ziprasidone-induced Acute Laryngeal Dystonia. Prog Neuropsychopharmacol Biol Psychiatry 2007;31:970. Miyamoto S, Duncan GE, Marx CE, Lieberman JA. Treatments for schizophrenia: a critical review of pharmacology and mechanisms of action of antipsychotic drugs. Mol Psychiatry 2005;10:79-104. Rosenfield PJ, Girgis RR, Gil R. High-dose ziprasidone-induced acute dystonia. Prog Neuropsychopharmacol Biol Psychiatry 2007;31:546–7.
We appreciate Dr. Duggal's interest in our case report (Rosenfield et al., 2007). We feel that his report of an acute laryngeal dystonia after treatment with ziprasidone (Duggal, 2007), in addition to our case report of a more generalized ziprasidone-induced dystonic reaction (Rosenfield et al., 2007) will help to increase awareness of the risks of these reactions with second generation antipsychotics. Dr. Duggal's patient was next treated with a relatively high dose of risperidone (i.e., 8 mg) and did not experience any further laryngeal dystonias (Duggal, 2007). This may have been because he was treated with prophylactic benztropine given the potentially increased risk of extrapyramidal side effects at higher doses of risperidone (Miyamoto et al., 2005). Further research needs to be done to understand which individuals are at greatest risk for dystonic reactions after treatment with the newer second generation antipsychotics, such as ziprasidone.
0278-5846/$ - see front matter © 2007 Elsevier Inc. All rights reserved. doi:10.1016/j.pnpbp.2007.01.026
Ragy R. Girgis* Paul J. Rosenfield Roberto Gil Department of Psychiatry, Columbia University, New York State Psychiatric Institute, United States ⁎ Corresponding author. E-mail address: [email protected]. 27 January 2007